Clinical Trial Update: A Study of PCSK9 Inhibitor AK102 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the PCSK9 inhibitor AK102 in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• AK102

Snippet

Sponsor: Akeso | Conditions: Hypercholesterolaemia | Phase 1 | Status: COMPLETED